Evidence map›Paper›PMID 22990745›Full record

ArticleCancer2013

UBE4B levels are correlated with clinical outcomes in neuroblastoma patients and with altered neuroblastoma cell proliferation and sensitivity to epidermal growth factor receptor inhibitors.

Peter E Zage, Natalie Sirisaengtaksin, Yin Liu, Monica Gireud, Brandon S Brown, Shana Palla, Kristen N Richards, Dennis P M Hughes, Andrew J Bean

Abstract read
In one paragraph

Article in Cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Development of FeCancer nanotechnology · 2021
    Article
  9. Article
  10. Review
  11. Article
  12. Regulation of the p53 Family Proteins by the Ubiquitin Proteasomal Pathway.International journal of molecular sciences · 2019
    Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Peter E ZageDepartment of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine, Houston, Texas, USA. zage@bcm.tmc.edu
Natalie Sirisaengtaksin
Yin Liu
Monica Gireud
Brandon S Brown
Shana Palla
Kristen N Richards
Dennis P M Hughes
Andrew J Bean
The University of Texas Health Science Center at Houston · USThe University of Texas MD Anderson Cancer Center · USBaylor College of Medicine · US

Funding

U OF TEXAS HLTH SCI CTR HOUSTON CENTER FOR CLINICAL AND TRANSLATIONAL SCIENCESUL1RR024148 · NCRR · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MCPHERSON, DAVID D · 2006 to 2010
$27.9M
MOLECULAR MECHANISMS OF NEUROTRANSMITTER SECRETIONR01MH058920 · NIMH · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI BEAN, ANDREW J · 1998 to 2010
$2.9M
Preclinical Evaluation of ERBB Family Members as Therapeutic Targets in OsteosarcR01CA149501 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KLEINERMAN, EUGENIE S · 2010 to 2015
$1.7M
Bayesian Methods in Signal Transduction Network AnalysisR01LM010022 · NLM · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI LIU, YIN · 2011 to 2014
$901k
NCI NIH HHS R01 CA149501NCRR NIH HHS UL1 RR024148NIMH NIH HHS R01 MH058920NIMH NIH HHS R01 MH58920NLM NIH HHS R01 LM010022
6 · The paper itself

Abstract

backgroundThe UBE4B gene, which is located on chromosome 1p36, encodes a ubiquitin ligase that interacts with hepatocyte growth factor-regulated tyrosine kinase substrate (Hrs), a protein involved in epidermal growth factor receptor (EGFR) trafficking, suggesting a link between EGFR trafficking and neuroblastoma pathogenesis. The authors analyzed the roles of UBE4B in the outcomes of patients with neuroblastoma and in neuroblastoma tumor cell proliferation, EGFR trafficking, and response to EGFR inhibition.

methodsThe association between UBE4B expression and the survival of patients with neuroblastoma was examined using available microarray data sets. UBE4B and EGFR protein levels were measured in patient tumor samples, EGFR degradation rates were measured in neuroblastoma cell lines, and the effects of UBE4B on neuroblastoma tumor cell growth were analyzed. The effects of the EGFR inhibitor cetuximab were examined in neuroblastoma cells that expressed wild-type and mutant UBE4B.

resultsLow UBE4B gene expression is associated with poor outcomes in patients with neuroblastoma. UBE4B overexpression reduced neuroblastoma tumor cell proliferation, and UBE4B expression was inversely related to EGFR expression in tumor samples. EGFR degradation rates correlated with cellular UBE4B levels. Enhanced expression of catalytically active UBE4B resulted in reduced sensitivity to EGFR inhibition.

conclusionsThe current study demonstrates associations between UBE4B expression and the outcomes of patients with neuroblastoma and between UBE4B and EGFR expression in neuroblastoma tumor samples. Moreover, levels of UBE4B influence neuroblastoma tumor cell proliferation, EGFR degradation, and response to EGFR inhibition. These results suggest UBE4B-mediated growth factor receptor trafficking may contribute to the poor prognosis of patients who have neuroblastoma tumors with 1p36 deletions and that UBE4B expression may be a marker that can predict responses of neuroblastoma tumors to treatment.

Indexed as

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedCell Line, TumorCell ProliferationCetuximabChromosome DeletionChromosomes, Human, Pair 1ErbB ReceptorsHumansNeuroblastomaTreatment OutcomeTumor Suppressor ProteinsUbiquitin-Protein Ligase ComplexesUbiquitin-Protein LigasesAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedCetuximabEGFR protein, humanErbB ReceptorsTumor Suppressor ProteinsUBE4B protein, humanUbiquitin-Protein Ligase ComplexesUbiquitin-Protein Ligases

Identifiers

PMID22990745
PMCPMC3527637
OpenAlexW1495830234

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.